Abeona Therapeutics Inc. Common Stock

ABEONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
7.19 USD
↘ 0.06 (0.76%)🟢PRE MARKET (AS OF 04:17 AM EDT)
🟢Market: OPEN

ABEO is currently priced at $7.19. ABEO shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (45.6%), a bullish Golden Cross on the moving averages and bullish moving average alignment. ABEO is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Aug 10, 2026.

Open?$7.43
High?$7.44
Low?$7.19
Prev. Close?$7.24
Volume?4
Avg. Volume?1.3M
VWAP?$7.44
Rel. Volume?0.00x
Bid / Ask
Bid?$6.10 × 100
Ask?$8.40 × 100
Spread?$2.30
Midpoint?$7.25
Valuation & Ratios
Market Cap?424.6M
Shares Out?57.0M
Float?47.4M
Float %?83.1%
P/E Ratio?6.42
P/B Ratio?2.93
EPS?$1.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
226
Market Cap
412.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.abeonatherapeutics.com
Listed
1980-09-19
Address
6555 CARNEGIE AVE, 4TH FLOOR
CLEVELAND, OH 44103
Phone: 646-813-4701
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
16
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.15Distress
Confidence?56%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?27.93%Squeeze Risk
Short Interest?13.2M
Days to Cover?8.3
Free Float47.4M
Avg Daily Volume1.6M
Settlement Date2026-07-15
Financial Health
Current Ratio?5.89Strong
Quick Ratio?5.70Strong
Cash Ratio?1.98Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
73/100
P/E?
Peers
100
S&P
97
6.4CHEAP▾
P/B?
Peers
100
S&P
57
2.93CHEAP▾
P/S?
Peers
100
S&P
3
29.20HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.2CHEAP▾
EV/Sales?
Peers
100
S&P
3
26.23HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
90
45.6%STRONG▾
ROA?
Peers
50
S&P
97
33.3%STRONG▾
Cash Flow & Enterprise
FCF?$-85237000
Enterprise Value?$381.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist